<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="45457">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02514499</url>
  </required_header>
  <id_info>
    <org_study_id>UPCC 07914</org_study_id>
    <nct_id>NCT02514499</nct_id>
  </id_info>
  <brief_title>Multiplex Testing for Evaluation of Breast Cancer Risk, Longitudinal Study</brief_title>
  <official_title>Multiplex Testing for Evaluation of Breast Cancer Risk, Longitudinal Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Abramson Cancer Center of the University of Pennsylvania</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Abramson Cancer Center of the University of Pennsylvania</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The overall goal of the proposed research is to evaluate the uptake of testing and
      longitudinal risks and benefits of multiplex testing for cancer susceptibility in BRCA1/2
      negative patients. This model will inform the selection of the outcomes and potential
      mediators and moderators of these outcomes, to inform the debate over utility, risks, and
      benefits of clinical incorporation of multiplex testing for breast cancer susceptibility.
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>July 2014</start_date>
  <primary_completion_date type="Anticipated">July 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Screening</primary_purpose>
  </study_design_info>
  <primary_outcome>
    <measure>Completion of questionnaires</measure>
    <time_frame>2 years</time_frame>
  </primary_outcome>
  <enrollment>350</enrollment>
  <condition>BRCA1/2 Negative</condition>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Questionnaires</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  1. Women and men (at least 18 YO) 2. English speaking AND 3. Negative for BRCA1 and
             BRCA2 mutations

        Exclusion Criteria:

        1. Non English speaking patients
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Abramson Cancer Center of the University of Pennsylvania</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2016</verification_date>
  <lastchanged_date>January 10, 2017</lastchanged_date>
  <firstreceived_date>July 31, 2015</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>patients</keyword>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
